Recruiting PHASE1 INTERVENTIONAL 2-arm NCT06760455

A Safety and Tolerability Study of BPR-30221616 Injection in Healthy Subjects

A Single-center, Double-blind, Placebo-controlled, Dose-escalation Phase I Clinical Study to Evaluate the Safety and Tolerability of BPR-30221616 Injection in Healthy Subjects

Sponsor: Chengdu Brilliant Pharmaceutical Co., Ltd.

Conditions Healthy Participants

Interventions BPR-30221616 Injection Sodium Chloride Injection

Updated 2 times since 2025 Last updated: Feb 8, 2025 Started: Jan 10, 2025 Primary completion: Jan 24, 2026 Completion: Dec 5, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy Participants and is currently actively recruiting participants. Chengdu Brilliant Pharmaceutical Co., Ltd. leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

2 versions recorded

Mar 2025 — Present [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Feb 2025 — Mar 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

Jan 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chengdu Brilliant Pharmaceutical Co., Ltd.

Data source: Chengdu Brilliant Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China